Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Protara Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 33 | 31 | −2 |
| Shares | 5.93M | 5.66M | −269.2K (−4.5%) |
| Value | $18.4M | $16.7M | −$1.67M (−9.1%) |
New holders (2)
Institutions that held Protara Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Privium Fund Management (UK) Ltd | 35,000 | $104.0K | 0.13% |
| Financial Advocates Investment Management | 1,161 | – | – |
Sold out (4)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| DLD Asset Management, LP | 157,349 | $461.0K |
| Susquehanna International Group, LLP | 15,969 | $47.0K |
| Tower Research Capital LLC (TRC) | 1,807 | $5.00K |
| JPMorgan Chase & Co | 352 | $1.00K |